We are live on ! Find out more
SC

SMA Capital Portfolio holdings

AUM $238M
This Fund
S&P 500
This Quarter Est. Return
+14.62%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$238M
AUM Growth
+$6.45M
Cap. Flow
-$11.8M
Cap. Flow %
-4.96%
Top 10 Hldgs %
37.07%
Holding
184
New
89
Increased
22
Reduced
10
Closed
63

Top Buys

Rank Stock Value
1
CRH icon
CRH
CRH
+$7.92M
2
ITT icon
ITT
ITT
+$7.28M
3
PKG icon
Packaging Corp of America
PKG
+$7.02M
4
JBHT icon
JB Hunt Transport Services
JBHT
+$6.42M
5
TDY icon
Teledyne Technologies
TDY
+$6.3M

Top Sells

Rank Stock Value
1
BA icon
Boeing
BA
+$10.3M
2
ETN icon
Eaton
ETN
+$10.1M
3
CAT icon
Caterpillar
CAT
+$9.48M
4
FERG icon
Ferguson
FERG
+$8.32M
5
LIN icon
Linde
LIN
+$7.49M

Sector Composition

Rank Sector Weight
1 Industrials 55.56%
2 Consumer Discretionary 17.53%
3 Technology 8.66%
4 Materials 6.15%
5 Consumer Staples 4.87%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
COGT icon
101
Cogent Biosciences
COGT
$6.36B
$11.1K ﹤0.01%
287
+130
+83% +$4.55K
OCUL icon
102
Ocular Therapeutix
OCUL
$2.37B
$10.8K ﹤0.01%
1,098
+525
+92% +$4.76K
DNTH icon
103
Dianthus Therapeutics
DNTH
$6.16B
$10.7K ﹤0.01%
+110
New +$9.61K
TARS icon
104
Tarsus Pharmaceuticals
TARS
$3.09B
$10.6K ﹤0.01%
169
+89
+111% +$5.69K
XENE icon
105
Xenon Pharmaceuticals
XENE
$5.97B
$10.4K ﹤0.01%
173
+34
+24% +$1.89K
MLYS icon
106
Mineralys Therapeutics
MLYS
$2.28B
$10.4K ﹤0.01%
387
+179
+86% +$4.91K
ACAD icon
107
Acadia Pharmaceuticals
ACAD
$5.07B
$10.4K ﹤0.01%
+412
New +$9.06K
ERAS icon
108
Erasca
ERAS
$6.51B
$10.4K ﹤0.01%
+569
New +$8.14K
RCUS icon
109
Arcus Biosciences
RCUS
$3.9B
$10.4K ﹤0.01%
338
+80
+31% +$1.98K
ADPT icon
110
Adaptive Biotechnologies
ADPT
$4.15B
$10.4K ﹤0.01%
+485
New +$7.43K
ALKS icon
111
Alkermes
ALKS
$8.22B
$10.4K ﹤0.01%
+198
New +$7.73K
ELVN icon
112
Enliven Therapeutics
ELVN
$4.45B
$10.4K ﹤0.01%
+204
New +$8.66K
RARE icon
113
Ultragenyx Pharmaceutical
RARE
$2.58B
$10.4K ﹤0.01%
+310
New +$7.7K
CLDX icon
114
Celldex Therapeutics
CLDX
$3.16B
$10.3K ﹤0.01%
+278
New +$8.98K
RLAY icon
115
Relay Therapeutics
RLAY
$4.25B
$10.3K ﹤0.01%
+552
New +$8.01K
PTGX icon
116
Protagonist Therapeutics
PTGX
$9.72B
$10.3K ﹤0.01%
+84
New +$8.77K
VERA icon
117
Vera Therapeutics
VERA
$2.61B
$10.3K ﹤0.01%
+239
New +$8.91K
EWTX icon
118
Edgewise Therapeutics
EWTX
$4.73B
$10.2K ﹤0.01%
+252
New +$8.69K
RYTM icon
119
Rhythm Pharmaceuticals
RYTM
$7.74B
$10.2K ﹤0.01%
+92
New +$8.32K
MIRM icon
120
Mirum Pharmaceuticals
MIRM
$5.93B
$10.2K ﹤0.01%
+87
New +$8.73K
SUPN icon
121
Supernus Pharmaceuticals
SUPN
$2.63B
$10K ﹤0.01%
+216
New +$10.4K
ACLX
122
DELISTED
Arcellx
ACLX
– –
-53
Closed -$6.08K
APD icon
123
Air Products & Chemicals
APD
$68.6B
– –
-25,483
Closed -$7.4M
APLS
124
DELISTED
Apellis Pharmaceuticals
APLS
– –
-294
Closed -$11.8K
ARQT icon
125
Arcutis Biotherapeutics
ARQT
$3.15B
– –
-239
Closed -$5.63K
3 4
5
6 7

Similar funds

RMC
Ring Mountain Capital Tiburon, California $238M AUM 61.63% 1-Year Est. Return
PFA
Pinnacle Family Advisors Springfield, Missouri $238M AUM 28.94% 1-Year Est. Return
TCM
Tandem Capital Management Woodcliff Lake, New Jersey $238M AUM 38.59% 1-Year Est. Return
SAM
Soviero Asset Management New York $238M AUM 137.99% 1-Year Est. Return
CWM
Collaborative Wealth Management Lake Mary, Florida $238M AUM 17.65% 1-Year Est. Return
GRWP
Green Ridge Wealth Planning Montville, New Jersey $238M AUM
CNBOF
City National Bank of Florida Miami, Florida $238M AUM 29.9% 1-Year Est. Return
NSB
Norway Savings Bank Portland, Maine $239M AUM 41.7% 1-Year Est. Return

SMA Capital's Q2 2026 Portfolio in Review

As of Q2 2026, SMA Capital held 184 positions worth $238M, up 2.8% from $232M the previous quarter. Its ten largest holdings account for 37% of the portfolio.

SMA Capital withdrew a net $11.8M in Q2 2026, closing 63 positions and reducing 10 holdings. Its most notable exit was Boeing, an estimated $10.3M position sold in full.

By sector, the portfolio is most concentrated in Industrials at 56% of assets, down from 79% a quarter earlier, followed by Consumer Discretionary and Technology.

Against the trend, SMA Capital opened a new position in CRH worth $7.7M.

  • SMA Capital's largest Q2 2026 buy was CRH: 72,000 shares worth $7.7M.
  • SMA Capital added most to Ametek in Q2 2026, an estimated $2.33M increase.
  • SMA Capital's biggest Q2 2026 reduction was Applied Industrial Technologies, cutting an estimated $5.83M.
  • SMA Capital fully exited Boeing in Q2 2026, selling an estimated $10.3M.
  • SMA Capital's ten largest holdings make up 37% of its $238M portfolio in Q2 2026.
  • SMA Capital opened 89 new positions and closed 63 in Q2 2026.
  • SMA Capital's portfolio value rose 2.8% quarter-over-quarter to $238M.

Based on SMA Capital's 13F filing for Q2 2026, filed 14 Aug 2026.